PRINCETON, N.J., July 19 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that its partner MedImmune, Inc. has
initiated a Phase Ib multi-dose clinical trial of MEDI-545 for the
potential treatment of systemic lupus erythematosus (SLE or lupus).
MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human
Antibody Development System(R).
MedImmune is also evaluating MEDI-545 in a Phase I single-dose trial in
lupus patients and a Phase I dose-escalation trial in psoriasis patients.
Preliminary data from the Phase I single-dose trial in lupus showed an
acceptable safety profile and tolerability of MEDI-545 in patients, as
presented at the 8th International Lupus Consortium, held May 24-26, 2007
in Shanghai. MedImmune plans to begin an additional trial for MEDI-545 in
idiopathic inflammatory myositis, an immunological disease that involves
chronic muscle inflammation, pain and weakness.
"We are pleased with the advances that MedImmune continues to make in
the development of MEDI-545. We believe that the ongoing studies as well as
studies in new indications hold the promise of delivering new therapeutic
options to patients living with autoimmune diseases," said Howard H. Pien,
President and CEO of Medarex.
About MEDI-545
MEDI-545 (previously known as MDX-1103) is a fully human monoclonal
antibody targeting interferon-alpha. Published data indicate that levels of
interferon-alpha are elevated in many patients with active SLE and other
autoimmune disorders, and may be associated with disease activity.
Preclinical data from animal models suggest that MEDI-545 may suppress the
abnormal immune activity associated with lupus by binding to multiple
interferon-alpha subtypes seen in the serum of lupus patients.
In November 2004, MedImmune entered into a collaboration with Medarex
to focus on two specific antibodies, one of which was MDX-1103 (now known
as MEDI-545). Under the terms of the agreement, MedImmune is responsible
for all ongoing clinical development activities. Prior to the beginning of
pivotal studies, Medarex may elect to co-develop the products in return for
the opportunity to co-promote and to receive a share of the commercial
profits in the United States. In all other cases, Medarex will be entitled
to receive milestone payments and royalties.
About Lupus
Approximately 350,000 individuals in the United States are affected
with lupus, a chronic inflammatory disease that causes the body to attack
its own tissues and organs, including the skin, joints, blood and kidneys.
Treatments for lupus include anti-inflammatory drugs, antimalarials,
corticosteroids and drugs approved for other purposes, such as
immunosuppressive agents given to cancer patients undergoing chemotherapy
or medicines developed to treat arthritis patients. Lupus occurs about 10
times more frequently in adult females than adult males, and is two to
three times more common among African Americans, Hispanics, Asians and
Native Americans.
About Medarex, Inc.
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 30 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase III clinical trials. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com .
Statement on Cautionary Factors
Except for the historical information presented herein, matters
discussed herein may constitute forward-looking statements that are subject
to certain risks and uncertainties that could cause actual results to
differ materially from any future results, performance or achievements
expressed or implied by such statements. Statements that are not historical
facts, including statements preceded by, followed by, or that include the
words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect";
"estimate"; "could"; "may"; or similar statements are forward-looking
statements. Medarex disclaims, however, any intent or obligation to update
these forward-looking statements. Risks and uncertainties include
uncertainties related to the outcome of clinical trials, slower than
expected rates of patient recruitment, unforeseen safety issues resulting
from the administration of MEDI-545 in patients, risks relating to
MedImmune, Inc. deciding to stop or delay future clinical development with
respect to MEDI-545, to stop or delay the Phase I clinical trial, or to
stop or delay future trials relating to MEDI-545 as well as risks detailed
from time to time in Medarex's public disclosure filings with the U.S.
Securities and Exchange Commission (SEC), including its Annual Report on
Form 10-K for the fiscal year ended December 31, 2006. There can be no
assurance that such development efforts will succeed or that other
developed products will receive required regulatory clearance or that, even
if such regulatory clearance were received, such products would ultimately
achieve commercial success. Copies of Medarex's public disclosure filings
are available from its investor relations department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html /
CONTACT:
Laura S. Choi, Investor Relations,
+1-609-430-2880, x2216, or Jean Mantuano, Corporate
Communications (media), +1609-430-2880, x2221, both of Medarex,
Inc.
|
